# A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance

Source: https://onco.cc/trials/nct07321015/  
OnCo record `nct07321015` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance is a phase 2, interventional study registered as NCT07321015 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 72 participants, started 2026-01-20 and due to reach its primary completion in 2027-11-30. Interventions recorded: Fluzoparib Monotherapy. Conditions listed: Platinum-sensitive; TNBC, Triple Negative Breast Cancer; BRCA1/2 Mutation or Not. Triple-negative eligibility wording from the registry: "Histologically confirmed triple-negative breast cancer (TNBC; ER \<1%, PR \<1%, HER2-negative)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: Fzp-MA-TNBC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07321015
- Phase: 2
- Setting: An Exploratory Single-Arm Study of Maintenance Fluzoparib in Platinum-Sensitive, Advanced Triple-Negative Breast Cancer Patients With BRCA1/2 Mutation or Wild-Type BRCA
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT07321015: https://clinicaltrials.gov/study/NCT07321015

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07321015.json